B C I PHARMA has a total of 11 patent applications. It decreased the IP activity by 75.0%. Its first patent ever was published in 2017. It filed its patents most often in Australia, Brazil and Canada. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are VERNALIS CAMBRIDGE LTD, VERNALIS R & D LTD and STANGELAND ERIC L.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 1 | |
#2 | Brazil | 1 | |
#3 | Canada | 1 | |
#4 | EPO (European Patent Office) | 1 | |
#5 | Israel | 1 | |
#6 | Republic of Korea | 1 | |
#7 | Mexico | 1 | |
#8 | Singapore | 1 | |
#9 | United States | 1 | |
#10 | WIPO (World Intellectual Property Organization) | 1 | |
#11 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Heterocyclic compounds | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Amiable Claire | 7 |
#2 | Surleraux Dominique | 7 |
#3 | Guillon Rémi | 4 |
#4 | Rémi Guillon | 3 |
#5 | Dominique Surleraux | 3 |
#6 | Claire Amiable | 3 |
#7 | Guillon Remi | 3 |
#8 | Dieudonné François-Xavier | 1 |
#9 | Louat Thierry | 1 |
#10 | Deroo Sabrina | 1 |
Publication | Filing date | Title |
---|---|---|
WO2021023888A1 | Isoquinoline derivatives as protein kinase inhibitors | |
US2019127379A1 | Adenine derivatives as protein kinase inhibitors |